Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop Organized by the FDA and MRA

13 November 2019 | Events, Science, Treatment


Neoadjuvant Workshop

On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.

Keynote Lecture: A role and rationale for neoadjuvant therapy in the melanoma treatment landscape & Session 1: Foundational Experience from Other Areas in Oncology 

Presentation 1: Dr. Suzanne Topalian
Presentation 2: Dr. Angela DeMichele
Presentation 3: Dr. Patricke Forde
Presentation 4: Dr. Laleh Amiri-Kordestani
Presentation 5: Dr. Donald Berry

Session 2: Current Melanoma Neoadjuvant Experience

Presentation 6: Dr. Caroline Robert
Presentation 7: Dr. Jennifer Wargo
Presentation 8: Dr. Janis Taube

Session 3: Optimal Clinical Trial Design and Patient Selection

Presentation 9: Dr. Charlotte Ariyan
Presentation 10: Dr. Michael Atkins
Presentation 11: Dr. Christian Blank
Presentation 12: Dr. Rajeshwari Sridhara

Panel Discussion with Audience Q&A – Working Together to Develop Neoadjuvant Therapies in Melanoma

 

Login

×